NCNA beat EPS expectations by 35.84%
Nov 28, 2024, 11:34 PM
0.00%
What does NCNA do
NuCana PLC is a UK-based biopharmaceutical company focused on cancer treatments using ProTide technology, with candidates NUC-3373 and NUC-7738 currently in Phase I/II clinical trials. The company's pipeline also includes Acelari, a ProTide transformation of gemcitabine.
NuCana plc (NCNA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, NuCana plc's actual EPS was -$1.75, beating the estimate of -$2.73 per share, resulting in a 35.84% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.